A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
about
Minority Representation in Migraine Treatment Trials.AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacksEmerging treatments for the primary headache disorders.A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine.The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine.Update on the Pharmacological Treatment of Chronic Migraine.New treatments for headache.Sumatriptan iontophoretic transdermal system for acute treatment of episodic migraine.The efficacy and safety of sumatriptan intranasal powder in adults with acute migraine.Sumatriptan Nasal Powder: A Review in Acute Treatment of Migraine.Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan.AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine.Intranasal immunization with dry powder vaccines.AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial.A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis.Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine.
P2860
Q30238764-ABFD283F-7770-486E-9886-5D6D4640DFB6Q36380205-5232D1ED-FB05-4285-8003-F8860B5D8047Q38504746-6D342F8C-0213-4759-B9AA-CDB8A7251172Q38539637-C73CEACE-31A3-4BCC-A4C7-44D14C19A35CQ38563244-A059A884-3586-46E0-A617-64CC2774BDA2Q38686130-E30F463F-B611-4500-AAEC-BA9641FF6E68Q38773593-6EC12C0A-D000-4285-9DC0-0A68C44361FAQ38804198-20AE366E-F78B-401A-9758-7A3C47F2F7D2Q38853704-7969E857-97E5-4DC9-A092-D9EB9146D41FQ38967012-995364CA-D862-4486-A8C4-C7F5655AE67AQ39155775-84241038-B7F9-434E-B77B-198AC89C3279Q39366862-80FC6C84-28ED-4B47-A77A-02506D11470DQ47584590-6514F3AF-D605-4E5E-B4EC-2F2364D33A2AQ47742941-76BF9EFB-DF57-46AC-9F2D-31E9A2B6BB84Q47749005-16EB2003-7AB8-478C-8619-057900618EF9Q47932320-2D5C1671-D4ED-4AE5-9162-1F998FB154BEQ54920214-A5BB3CC5-D49D-4E2F-B302-F3FD86CA2E10
P2860
A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A randomized, double-blind, pl ...... e migraine (The TARGET Study).
@ast
A randomized, double-blind, pl ...... e migraine (The TARGET Study).
@en
type
label
A randomized, double-blind, pl ...... e migraine (The TARGET Study).
@ast
A randomized, double-blind, pl ...... e migraine (The TARGET Study).
@en
altLabel
A randomized, double-blind, pl ...... te migraine (The TARGET Study)
@en
prefLabel
A randomized, double-blind, pl ...... e migraine (The TARGET Study).
@ast
A randomized, double-blind, pl ...... e migraine (The TARGET Study).
@en
P2093
P2860
P921
P356
P1433
P1476
A randomized, double-blind, pl ...... e migraine (The TARGET Study).
@en
P2093
Egilius L H Spierings
Jennifer Carothers
John Messina
Per G Djupesland
Peter J McAllister
Ramy A Mahmoud
Roger K Cady
P2860
P304
P356
10.1111/HEAD.12472
P407
P577
2014-10-30T00:00:00Z